ASH 2020 AML In-depth

Complete Coverage

Azacitidine vs Decitabine in Unfit, Newly Diagnosed Acute Myeloid Leukemia

Decitabine With Venetoclax as Salvage Therapy in R/R Acute Myeloid Leukemia

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.

Venetoclax in Combination With FLAG-IDA Is Efficacious in Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

A nurse reviews a prescription with a patient.

Does Prior TKI Therapy Affect Outcomes in R/R AML Treated With Gilteritinib?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fu

Antileukemic Activity Seen With Flotetuzumab in Primary Induction Failure, Early-Relapse AML

A patient receives an IV drip.

Cytarabine in Young Adults With AML: Subcutaneous Injection Noninferior to IV Infusion

Hospice nurse checks on senior female patient.

Sociodemographic Characteristics a Strong Factor in EOL Healthcare Utilization in Acute Myeloid Leukemia

Next post in ASH 2020 AML In-depth

Decitabine With Venetoclax as Salvage Therapy in R/R Acute Myeloid Leukemia